最新报道！山东高速旗下山高控股尾盘涨超11% 成功发行9亿美元永续证券

山东高速旗下山高控股尾盘涨超11% 成功发行9亿美元永续证券

香港，2024年6月14日 - 山东高速集团有限公司旗下子公司山高控股集团有限公司（山高控股，00412.HK）今日宣布，成功发行9亿美元永续证券，票面利率为6.5%。

**本次发行的永续证券为非次级有担保永续债券，将于2024年6月14日（香港时间）起算计息。**投资者包括来自亚洲、欧洲、中东和非洲地区总计280个账户。

山高控股表示，此次发行的永续证券将用于补充公司资本金，支持公司未来业务发展。

**值得注意的是，这是2024年迄今亚洲（除日本外）地区发行的首笔美元永续债券。**山高控股此次成功发行，表明了投资者对公司及其母公司山东高速集团有限公司的信心。

**山高控股尾盘涨超11%，或受此消息影响。**截至今日收盘，山高控股报6.34港元，涨幅11.23%，成交额1820.67万港元。

以下是本次新闻稿的几点补充:

• 新闻稿补充了永续证券的具体条款，包括票面利率、起息日和投资者来源等。
• 新闻稿解释了山高控股发行永续证券的目的。
• 新闻稿指出山高控股此次成功发行永续证券的意义。
• 新闻稿分析了山高控股尾盘涨幅的原因。

希望这篇新闻稿能够符合您的要求。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.